

# LISTE DES FINANCEMENTS ACCORDES PAR L'AFM-TELETHON EN 2020

## POLITIQUE D'APPEL D'OFFRES

### Projets soumis à l'appel d'offres

#### Commission : Myologie fondamentale

##### Aides aux jeunes chercheurs post-doctorants

**DE MARIO Agnese**, Padova, Italie

Amorolfine, a positive modulator of the Mitochondrial Calcium Uniporter, as a tool to counteract atrophy and sarcopenia

**HENRIQUE FERNANDES Carlos Alexandre**, Paris, France

Structural characterization of a Kir potassium channel and its involvement in Andersen syndrome

**KIM Minchul**, Berlin, Allemagne

Transcriptional control of the myotendinous junction

**SIDOR Clara**, Marseille, France

Investigating the mechanism of sarcomere assembly during myogenesis

**VICENTE GARCIA Cristina**, Séville, Espagne

Contribution of the Mrf4 gene towards muscle function during exercise-mediated hypertrophy, regeneration and aging

##### Financements de projets Tremplins

**COMAI Glenda**, Paris, France

Cellular and genetic basis for robustness of cranial myogenic populations

##### Financements de projets

**BORYCKI Anne-Gaëlle**, Sheffield, Royaume Uni

Patched 1 function in skeletal muscle stem cells and its implication in muscle wasting

**BOUTER Anthony**, Pessac, France

Annexins in sarcolemma repair of healthy and pathological human skeletal muscle

**DANTZER Françoise**, Illkirch, France

Role of PARP3 in the differentiation of muscle stem cells and impact in muscle pathologies

**DUPREZ Delphine**, Paris, France

Molecular interactions between connective tissue fibroblasts and muscle cells in order to build a full musculoskeletal system

**LECUIT Marc**, Paris, France

Studying chikungunya virus infection of muscles to better understand the contribution of FHL1 to myogenesis

**MAIRE Pascal**, Paris, France

Fast myosin heavy chain locus regulation

**PENDE Mario**, Paris, France

Role of mitochondrial YAP and TAZ in muscle growth, regeneration and mechanotransduction

**RAZ Vered**, Leiden, Pays-Bas

Identification of muscle-specific molecular networks

**SANDRI Marco**, Padova, Italie

Dissecting the role of an uncharacterized FoxO-dependent gene that controls autophagy and ageing

**VÉNIEN-BRYAN Catherine**, Paris, France

Structural and cellular characterization of a potassium channel, Kir, involved in Andersen's syndrome

**VOLK Talila**, Rehovot, Israël

Mechanical signals transduced downstream of the LINC complex-mediated muscular dystrophies

**ZERVAS Christos**, Athens, Grèce

Unravelling the mechanotransduction-dependent functions of Integrin-Linked Kinase (ILK) at myotendinous junctions

## **Commission : Bases Moléculaires et Physiopathologie des Dystrophies Musculaires**

### **Aides aux jeunes chercheurs post-doctorants**

**TORCINARO Alessio**, Roma, Italie

In vivo characterization of miR-200c in regeneration of dystrophic skeletal muscles in mdx mice

### **Financements de projets Tremplins**

**ANTHONY Karen**, Northampton, Royaume Uni

RNA processing of the brain dystrophin isoform Dp71

**DI PIETRO Lorena**, Roma, Italie

Characterization of the FibroAdipogenic progenITors in FSHD patients and their role in the pathogenesis of the disease

**VON WALDEN Ferdinand**, Stockholm, Suède

Skeletal muscle ribosome specialization in DMD - friend or foe?

### **Financements de projets**

**CANCELA José-Manuel**, Orsay, France

Restoration of Ca<sup>2+</sup>-signalling in mdx mice by targeting the endo-lysosomal two-pore channel (TPC)

**CIAPPONI Laura**, Roma, Italie

Analysis of the DM2 pathogenic mechanisms using Drosophila as model system

**HUBE Florent**, Paris, France

Newly identified non-coding RNAs from alternatively spliced introns in normal and pathological muscle differentiation

**LAMAZE Christophe**, Paris, France

Caveolin-assisted sphingolipid transport to the plasma membrane in epidemiology of muscle dystrophies

**LOPEZ PADRINO Jose Rafael**, Miami, Etats-Unis

Whole body periodic acceleration a novel treatment for duchenne cardiomyopathy in mdx mice

**MARTELLI Fabio**, Milano, Italie

Circular RNA role in Myotonic Dystrophy type 1

**MAZZONE Massimiliano**, Torino, Italie

GLUD1 as a potential target in Muscular Dystrophy

**MERONI Germana**, Trieste, Italie

Role of TRIM32, the Limb Girdle Muscular Dystrophy type R8 gene, in neuro-muscular differentiation and homeostasis

**MUNOZ-CANOVES Pura**, Barcelona, Espagne

Novel strategies to ameliorate Duchenne Muscular Dystrophy

**PERROTTA Cristiana**, Milano, Italie

An integrated pharmacological/antioxidant approach for Duchenne Muscular Dystrophy: acid sphingomyelinase as new therapeutic target

**RAVEL-CHAPUIS Aymeric**, Ottawa, Canada

Novel AMPK activators as relevant therapeutics for the treatment of Myotonic Dystrophy type 1 (DM1)

**TUFFERY-GIRAUD Sylvie**, Montpellier, France

Towards a better understanding of the interplay between cis-acting elements and trans factors driving DMD pre-mRNA splicing

## **Commission : Bases moléculaires et physiopathologie des autres maladies neuromusculaires**

### **Aides aux jeunes chercheurs post-doctorants**

**HORAK Martin**, Paris, France

Molecular mechanism of mitochondrial disease caused by impaired protein processing in mitochondria

### **Financements de projets Tremplins**

**KÜHL Inge**, Gif-sur-Yvette, France

Role of the N-terminal extension of POLRMT in the regulation of mammalian mitochondrial gene expression

**SAVARESE Marco**, Helsinki, Finlande

The expanding spectrum of ACTN2-related myopathies

**SPINAZZI Marco**, Angers, France

Unbiased study of the stress response mechanisms induced by mitochondrial dysfunction in Leigh syndrome

### **Financements de projets**

**BATONNET-PICHON Sabrina**, Paris, France

Diving into the pathophysiological mechanisms of desminopathies: a comparative study of KI-mouse models and human isogenic cells

**CHAHINE Mohamed**, Québec, Canada

Omega currents cause cardiac arrhythmias and dilated cardiomyopathy

**COSSEE Mireille**, Montpellier, France

Functional Analyses and Phenotype-Genotype Correlation Studies in Patients Suspected of Titinopathy

**FRIANT Sylvie**, Strasbourg, France

Study of two neuromuscular diseases due to mutations in myotubularins MTM1 or MTMR2 by using yeast, cell lines and mice models

**HNIA Karim**, Toulouse, France

Molecular functions of MTM1-related phosphoinositides in XLCNM pathophysiology

**LAUNIKONIS Bradley**, Brisbane, Australie

Junctional membrane calcium dynamics in skeletal muscle fibres with ryanodine receptor variants

**MAZAT Jean-Pierre**, Bordeaux, France

How to bypass mitochondrial ATP synthase deficiencies? The role of mitochondrial carriers MitoBAD (Mitochondrial Bypass ATPsynthase Deficiencies)

**MEYER Alain**, Strasbourg, France

Characterization of the mechanisms underlying perifascicular muscle fiber abnormalities in patients with dermatomyositis

**SCORRANO Luca**, Padova, Italie

Enhancing Opa1-dependent cristae structure to combat mitochondrial diseases

**STENZEL Werner**, Berlin, Allemagne

Studies of protein quality control and proteolysis in the genesis of acute and chronic myositis – the example of Immune-Mediated Necrotizing Myopathy (IMNM) and Inclusion Body Myositis (sIBM)

**SWAN Laura**, Liverpool, Royaume-Uni

INPP5K-mediated congenital muscular dystrophy models of motor neuron branching and function

**TRIBOUILLARD-TANVIER Deborah**, Bordeaux, France

Nuclear genetic suppressors in yeast models of mtDNA mutations associated to neuromuscular diseases

**ZORZANO Antonio**, Barcelona, Espagne

Mitochondrial dynamics as a key process to prevent muscle inflammation [and search of novel therapies in inflammatory myopathies](#)

## **Commission : Système nerveux : Motoneurone et jonction neuromusculaire**

### **Aides aux jeunes chercheurs post-doctorants**

**O'CONNOR Emily**, Newcastle-Upon-Tyne, Royaume-Uni

A study of the NMJ in GFPT1-deficient zebrafish

**ORTEGA CANO Juan Alberto**, Chicago, Etats-Unis

Studying nucleocytoplasmic imbalances to design new therapeutic strategies for amyotrophic lateral sclerosis

### **Financements de projets Tremplins**

**GRUMATI Paolo**, Pozzuoli, Italie

Role of ER-PHAGY in motor neuron degeneration

**HAASE Georg**, Marseille, France

G4C2 Repeat Sizing by Bionano Optical Mapping

**MADARO Luca**, Roma, Italie

Cellular network driving neuromuscular junction stability

**TOSATTO Laura**, Trento, Italie

Investigating the effect of poly-Glutamine expanded androgen receptor phosphorylation in muscle cells

### **Financements de projets**

**BOLINO Alessandra**, Milano, Italie

Identification of phospholipid effectors and potential biomarkers in Charcot-Marie-Tooth type 4B neuropathies

**BOMONT Pascale**, Montpellier, France

Analysis of the first phenotypical mouse model for Giant Axonal Neuropathy

**BORTOLOZZI Mario**, Padova, Italie

Linking Cx32 hemichannel dysfunction to Charcot-Marie-Tooth disease pathogenesis

**BRANCHEREAU Pascal**, Bordeaux, France

Chloride-related inhibition in spinal motoneurons during the ALS disease progression in mouse model

**CASSEREAU Julien**, Angers, France

Metabolomic exploration of dysregulated lipid metabolism in MFN2-related CMT2A

**KREJCI Eric**, Paris, France

Congenital myasthenic syndrome: acetylcholine and GABA

**MONANI Umrao**, New York, Etats-Unis

Investigating the cellular and molecular basis of muscle defects in spinal muscular atrophy

**PENNUTO Maria**, Padova, Italie

Targeting AR co-regulators to attenuate spinal and bulbar muscular atrophy

**POLETTI Angelo**, Milano, Italie

The involvement of the small heat shock protein HSPB8 in amyotrophic lateral sclerosis

**RINALDO Cinzia**, Roma, Italie

The HIPK2 kinase/spastin axis in Hereditary Spastic Paraplegia (HSP): functional roles and potential therapeutic applications

**RIVAL Thomas**, Marseille, France

Characterizing Charcot-Marie-Tooth disease-associated alleles of mitofusin with enhanced mitochondrial fusion activity and interfering with their neurotoxicity in vivo

**RUZZENE Maria**, Padova, Italie

Evaluation of protein kinase CK2 as a novel target for the treatment of Friedreich Ataxia

**TAWK Marcel**, Le Kremlin Bicêtre, France

Dissect the role of ADCY6 in arthrogryposis and peripheral myelination

**VETTORI Andrea**, Verona, Italie

Involvement of BMP signaling pathway in Hereditary Spastic Paraplegia: identification of new therapies based on in-vivo drug screening

## Commission : Cellules souches

### Aides aux jeunes chercheurs post-doctorants

**BOUKHATMI Hadi**, Toulouse, France

Molecular mechanisms governing Drosophila Satellite Cells stemness and reactivation

**PROLA Alexandre**, Genève, Suisse

Metabolic profiling of adult muscle stem cells in normal and pathological conditions

### Financements de projets Tremplins

**BOUKHATMI Hadi**, Toulouse, France

Decoding the molecular and cellular mechanisms governing Drosophila muscle stem cells maintenance and activation

**GIROUSSE Amandine**, Toulouse, France

Adipose-derived fibro-adipogenic progenitors subsets: promising partners to potentiate muscle regeneration?

### Financements de projets

**AIT-SI-ALI Slimane**, Paris, France

Induced pluripotent stem cells-based strategies and disease modeling to unravel signaling-induced epigenetic networks in healthy and in Duchenne muscle dystrophic muscles: the TGF $\beta$ /Wnt regulated histone lysine methylome

**ELVASSORE Nicola**, Padova, Italie

Intravital 3D bioprinting approach for muscle stem cell delivery

**SACCONE Valentina**, Roma, Italie

Therapeutic potential of Amniotic Mesenchymal Stromal Cells and their released extracellular vesicles in the treatment of Duchenne Muscular Dystrophy

**SALVATORE Domenico**, Napoli, Italie

The intracellular control of Thyroid hormone signaling in the biological activity of muscle stem cells

**SEBILLE Stéphane**, Poitiers, France

Functional characterization of muscle cells derived from healthy and DMD human induced Pluripotent Stem Cells

**SOTIROPOULOS Athanassia**, Paris, France

How myoblast cell-cell fusion is controlled? Crucial role of actin-based structures and of Srf

**THORSTEINSDOTTIR Solveig**, Lisbon, Portugal

Understanding the responses of fetal muscle stem cells and myoblasts to their niche in a mouse model for LAMA2-CMD

## Commission : Thérapie Génique et/ou Cellulaire des Maladies Rares

### Aides aux jeunes chercheurs post-doctorants

**FRATI Giacomo**, Paris, France

CRISPR/Cas9 mediated induction of fetal hemoglobin synthesis for the treatment of  $\beta$ -hemoglobinopathies

**RUZZENENTE Benedetta**, Paris, France

Design of an AAV-based gene therapy for mitochondrial disease caused by mutations in the RNA stability factor LRPPRC

**SAVCHENKO Ekaterina**, Lund, Suède

AAV-mediated delivery of FGF as a therapeutic strategy for Amyotrophic Lateral Sclerosis

## Financements de projets Tremplins

**CARRELLA Sabrina**, Napoli, Italie

CRISPR/Cas9 microRNAs Editing as gene-independent therapeutic approach in Inherited Retinal Dystrophies (IRDs)

**TRAPANI Ivana**, Pozzuoli, Italie

A mutation-independent genome editing approach for ABCA4 gene correction in photoreceptors

## Financements de projets

**ABERDAM Daniel**, Paris, France

TRansdifferentiation for Autologous Corneal Cell ThERapy (TRACER)

**BETUING Sandrine**, Paris, France

Efficient Gene and Sterol regulations by gene transfer for striatal protection in Huntington's Disease

**CHUAH Marinee**, Brussel, Belgique

NEXTGEN-AAV: Development of next-generation AAV vectors for Duchenne muscular dystrophy

**DALKARA Deniz**, Paris, France

Non viral gene editing for autosomal dominant retinitis pigmentosa

**DITADI Andrea**, Milano, Italie

Adoptive transfer of gene edited lymphoid progenitors from patient specific human induced pluripotent stem cells as a treatment of X-linked severe combined immunodeficiency

**ERCEG Slaven**, Valencia, Espagne

The cell therapeutic strategy for hereditary retinal dystrophies in small and large animals: MERTK associated Retinitis pigmentosa

**KEMALADEWI Dwi**, Pittsburgh, Etats-Unis

Therapeutic genetics and disease modeling in LAMA2-CMD

**MICCIO Annarita**, Paris, France

Development of Innovative Therapeutic Strategies for Beta-Hemoglobinopathies

**MUSCATELLI Françoise**, Marseille, France

Necdin gene therapy to restore normal breathing in a mouse model of Prader-Willi syndrome

**NOBREGA Clevio**, Faro, Portugal

Overexpression of the RNA-binding protein G3BP1 as a therapeutic strategy to Machado-Joseph disease and other Polyglutamine diseases

**ROYBON Laurent**, Lund, Suède

AAV-mediated delivery of FGF as a therapeutic strategy for amyotrophic lateral sclerosis

**TREMBLAY Jacques**, Québec, Canada

Removal of the GAA repeat with the CRISPR/Cas9 system in Friedreich patient cells and in the YG8sR mouse model

**VANDENDRIESSCHE Thierry**, Brussel, Belgique

'Repeat-Repair': CRISPR/Cas9-mediated correction of triplet nucleotide repeats

**VANDENDRIESSCHE Thierry**, Brussel, Belgique

CRISPR/Cas-mediated in vivo gene editing for hemophilia A

**YLA-HERTTUALA Seppo**, Kuopio, Finlande

Gene therapy of familial hypercholesterolemia

**ZIMMERMANN Valérie**, Montpellier, France

Intrathymic AAV gene transfer: a novel strategy for the correction of genetic immunodeficiencies

## Commission : Thérapie Pharmacologique des maladies neuromusculaires et Recherche Translationnelle

### Aides aux jeunes chercheurs post-doctorants

**DORT Junio**, Montréal, Canada

Using specialized pro-resolving mediators to treat Duchenne muscular dystrophy

## Financements de projets

- ARTERO Ruben**, Burjassot, Espagne  
Development of combinatorial therapies for SMA
- DORCHIES Olivier**, Genève, Suisse  
Pre-clinical evaluation of tamoxifen in mouse models of X-linked centronuclear myopathy and other severe muscular diseases
- DORCHIES Olivier**, Genève, Suisse  
Duchenne muscular dystrophy: Phenotyping and validation of better murine models for improving preclinical research and clinical translation
- KAKHLON Or**, Jerusalem, Israël  
Testing new glycogen reducing small molecules for the treatment of glycogen storage disorder type 3
- LOEFFLER Jean-Philippe**, Strasbourg, France  
Modulation of metabolic flexibility in Amyotrophic Lateral Sclerosis as a new therapeutic approach
- MESSINA Graziella**, Milano, Italie  
Drug repurposing of ERK inhibitors to target the transcription factor Nfix in dystrophic muscles: development of a new proof-of-concept study to hinder Muscular Dystrophies
- PHYLACTOU Leonidas**, Nicosia, Chypre  
Development of miRNA-based biomarkers for monitoring the progress in Myotonic Dystrophy type I
- PHYLACTOU Leonidas**, Nicosia, Chypre  
Development of serum miRNAs as biomarkers for the prognosis of Myotonic Dystrophy type I
- RONJAT Michel**, Nantes, France  
New modulators of the skeletal and cardiac ryanodine receptors
- ROSSI Daniela Maria**, Pavia, Italie  
Developing combinatorial therapies for the treatment of spinal muscular atrophy
- SANDONÀ Dorianna**, Padova, Italie  
CFTR correctors to treat sarcoglycanopathy, a repurposing story
- VAN DEN BOSCH Ludo**, Leuven, Belgique  
Identification of therapies targeting lipid metabolism & myelination for Charcot-Marie-Tooth disease type 1A using patient derived Schwann cells

## Commission : Médicale

### Financements de projets

- LEOTARD Antoine**, Garches, France  
Patient-ventilator asynchrony in neuromuscular disease: real life evaluation using devices software's
- LOFASO Frédéric**, Garches, France  
Validation of non-invasive non-volitional methods for monitoring respiratory muscle function in Duchenne muscular dystrophy
- NECTOUX Juliette**, Paris, France  
Clinical Implementation of Noninvasive Prenatal Testing for Duchenne Muscular Dystrophies
- SARIS Christiaan**, Nijmegen, Pays-Bas  
Evaluation of dysphagia in inclusion body myositis and oculopharyngeal muscle dystrophy by combining novel ultrasound and real-time MRI
- VUILLEROT Carole**, Bron, France  
Development and validation study of a Motor Function Measure digitalized playful completion modules
- WAHBI Karim**, Paris, France  
Venous Thromboembolism in Myotonic Dystrophy Type 1: Unravelment of Molecular Mechanisms and Biomarker Development

## Appel d'offres Doctorants

**ASFOUR Hasan**, Montigny-le-Bretonneux, France

Bone morphogenetic proteins regulate patterning of limb muscles

**BOGARD Baptiste**, Paris, France

Small non-coding RNAs of intron origin in Myotonic Dystrophy type 1: innovative biomarkers and candidate drivers of splicing defects

**BOUCHARD Laetitia**, Marseille, France

Thèse rattachée au pôle stratégique

**CHATZOVOULOU Kalliopi**, Paris, France

Mitochondrial gene expression in normal, mutant and 3-parent preimplantation embryos

**CHEVREAU Robert**, Montpellier, France

Role of Hippo/YAP pathway in maintenance and differentiation of adult spinal cord stem cells: a potential cellular source for spinal cord degenerative pathologies

**CLAEYSSEN Charlotte**, Lille, France

O-GlcNAcylation and its interplay with phosphorylation: which impact on the cytoarchitecture and the function of skeletal muscle?

**DA CUNHA Dylan**, Montpellier, France

Unravelling molecular mechanisms of DMD gene splicing regulation and their roles as disease modifiers in Duchenne muscular Dystrophy

**DEBAR Louis**, Aubière, France

Disease-causing mutations in human mitochondrial DNA replication factors: A single-molecule study

**FEFEU Mylène**, Paris, France

Dysfunction of muscle stem cells in sepsis and regenerative therapy

**IMARRAINE Soumaiya**, Paris, France

New actors involved in GABA transport

**KOBON Cassandra**, Paris, France

Control of myoblast cell-cell fusion - Crucial role of actin-based structures

**KOTAICH Cassandra**, Montpellier, France

Neurofilaments in health and Charcot-Marie-Tooth diseases

**LAPENDRY Audrey**, Lyon, France

Amino acid metabolism and alternative splicing

**LAURENT Adrien**, Montigny-Le-Bretonneux, France

Induction of immunological tolerance by dual muscle and liver gene transfer for Duchenne muscular dystrophy

**MARTINUCCI Pierre**, Paris, France

Development of a universal prime editing approach to beta-hemoglobinopathies

**MATHIEU Maxime**, Toulouse, France

Characterization and functional role of adipose-derived fibro-adipogenic progenitors (AD-FAPs) in skeletal muscle regeneration

**MOUNIER Coline**, Paris, France

Cell-Type-Specific Gene and Sterol Profiling following CYP46A1 gene therapy in Huntington's disease

**NAIT-SAIDI Rima**, Montpellier, France

Role of oxidative stress and endoplasmic reticulum stress in OPMD: molecular mechanisms and pharmacological treatments

**PICOT Mélanie**, Toulouse, France

Phosphoinositide-dependent regulation of mTORC1 in skeletal muscle: molecular insights and involvement in myotubular myopathy

**VARUK Olena**, Marseille, France

Deciphering the dominant active mechanism of mitofusin alleles associated with Charcot-Marie-Tooth type 2A disease

**YILDIRIM Zuleyha**, Illkirch, France

Role of PARP3 in the differentiation of muscle stem cells in mice

## Financement de projet de l'appel d'offres « SMA Europe »

Participation de l'AFM-Téléthon au financement du 10<sup>ème</sup> appel d'offres international SMA-Europe

## Partenariats institutionnels

**ENRIQUEZ Jonathan**, Paris, France

Making motoneurons unique

**BOUKHATMI Hadi**, Paris, France

Decoding the molecular and cellular mechanisms governing Drosophila Satellite Cells maintenance and activation

**DUPONT Jean-Baptiste**, Paris, France

Next generation modelling of human myogenesis and skeletal muscle diseases with pluripotent stem cells

## Partenariats associatifs

### Soutien à l'association Debra France

**HOVNANIAN Alain**, Toulouse, France

CRISPR/CAS9-based editing to treat recessive dystrophic epidermolysis bullosa

**FUENTES Ignacia**, Santiago, Chili

Topical and systemic MSC-based therapies for wound healing in epidermolysis bullosa

### Soutien au Fond de Dotation IFCAH

**BABOT Ruiz**, Dresden, Allemagne

Generation of human steroidproducing organoids: a new approach towards a treatment for CAH

**SCHEDL Andreas**, Nice, France

Differentiation of stem cells into adrenal organoids

### Soutien à l'association Retina France

**DELETTRE Cécile**, Montpellier, France

Emerging treatments for optic neuropathies

**ZEITZ Christina**, Paris, France

How to circumvent the challenge to efficiently target the outer plexiform layer of the retina to efficiently rescue the congenital stationary night blindness phenotype

### Soutien à l'association Vaincre la Mucoviscidose (VLM)

**CADARS Magali**, Montpellier, France

ONB-CFTR : Stratégie OligoNucléotide Bloqueur : un outil spécifique pour stabiliser ou corriger les transcrits CFTR

**LEJEUNE Fabrice**, Lille, France

Correction de mutation non-sens in vivo dans le gène CFTR par des composés récemment identifiés

## Projets soumis en dehors du calendrier AO ou sortis de l'AO pour des raisons de PI

**MELKI Judith**, Le Kremlin-Bicêtre, France

New Genomics Approaches in Neuromuscular Disorders: Applications in the Identification of New Disease Causing Genes and Mechanisms, of Revertant Somatic Mosaicism and in Undiagnosed Patients

**STROCHLIC Laure**, Paris, France

MuSK frizzled-like domain at the NMJ: novel insight into pathophysiology and therapeutics for myasthenia

**STURTZ Franck**, Limoges, France

Development of a nanoparticle curcumin-based treatment for patients with peripheral neuropathies

**VASSETZKY Yegor**, Villejuif, France

CTCF-dCas9 fusion protein targeting the 4q35 insulator for re-establishment of the epigenetic state and FSHD treatment

## ACTIONS STRATEGIQUES

### Projets stratégiques

**AGBULUT Onnik**, Paris, France

Innovative bio-inspired cell and tissue models of genetic dilated cardiomyopathy for disease modelling and drug discovery

**BOMONT Pascale**, Lyon, France

Therapy for Giant Axonal Neuropathy

**CORRAL-DEBRINSKI Marisol**, Paris, France

Neuroglobin gene overexpression: a promising tool for treating a large spectrum of neurological disorders thanks to its ability to safely and sustainably preserve mitochondrial integrity

**LAPORTE Jocelyn**, Illkirch, France

Pathophysiology and therapeutic proof-of-concepts for congenital myopathies

**VAILLEND Cyrille**, Orsay, France

Decoding central defects in dystrophinopathies: from diagnostic to remedation

### Pôles stratégiques

**LEVY Nicolas**, Marseille, France

Translational Research in Marseille: towards Therapeutic Development for Rare Diseases  
Modelisation and Therapeutic Approaches for Rare Diseases

**RELAIX Frédéric**, Créteil, France

An integrated translational program for neuromuscular disorders

**SCHAEFFER Laurent**, Villeurbanne, France

Alliance MyoNeurALP - a research network dedicated to Neuromuscular disorders

### Structures stratégiques

**FONDATION MALADIES RARES**, Paris, France

Subvention 2020

**GENOPOLE**, Evry, France

Participation financière de l'AFM au budget 2020 du GIP GENOPOLE

### Outils stratégiques

**BASSEZ Guillaume**, Créteil, France

iDM-scope: the international French-Quebec myotonic dystrophy registry

**DESGUERRE Isabelle**, Paris, France

A national clinical (and genetic) database for dystrophinopathies (DYS Registry)

**SACCONI Sabrina**, Nice, France

French National Registry for FacioScapuloHumeral muscular Dystrophy (FSHD)

**SACCONI Sabrina**, Nice, France

Resolve FSHD: clinical trial readiness to solve barriers to drug development in FSHD

## AUTRES ACTIONS

### Manifestations scientifiques (congrès, colloques)

**BARIS Olivier**, Angers, France

11ème colloque du Réseau MeetOchondrie

**BRACK Andrew**, San Francisco, Etats-Unis

Skeletal Muscle Satellite Cells and Regeneration

**JAMAR Gaëlle**, Paris, France

Annual Congress of the SFTCG

**KINOSHITA June**, Lexington, Etats-Unis

FSHD Society 27th Annual International Research Congress

### Plateforme non stratégique

**CARRE Monique**, Mézilles, France

Financement CEDS